Items where authors include "Parikh, O."

Article

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Huddart, R., Hafeez, S., Griffin, C. et al. (24 more authors) (2025) Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. European Urology, 87 (1). pp. 60-70. ISSN 0302-2838

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Huddart, R., Hafeez, S., Omar, A. et al. (25 more authors) (2023) Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. Clinical Oncology, 35 (9). pp. 586-597. ISSN 0936-6555

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Crabb, S.J. orcid.org/0000-0003-3521-9064, Hussain, S. orcid.org/0000-0003-1552-511X, Soulis, E. orcid.org/0000-0001-9022-9295 et al. (18 more authors) (2023) A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. Journal of Clinical Oncology, 41 (1). pp. 54-64. ISSN 0732-183X

Parker, C.C., James, N.D. orcid.org/0000-0002-7314-8204, Brawley, C.D. orcid.org/0000-0003-3641-278X et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Hussain, S.A. orcid.org/0000-0003-1552-511X, Lester, J.F., Jackson, R. et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE) : a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1470-2045

Clarke, N.W., Ali, A., Ingleby, F.C. et al. (47 more authors) (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Annals of Oncology, 30 (12). pp. 1992-2003. ISSN 0923-7534

Proceedings Paper

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: Disease control data. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S704-S705.

Huddart, R., Birtle, A., Cheung, K.C. et al. (19 more authors) (2023) Randomised phase II trial of adaptive image guided bladder radiotherapy: patient reported outcomes. In: Radiotherapy & Oncology. ESTRO 2023, 13-16 May 2023, Vienna, Austria. Elsevier , S331-S332.

Huddart, R.A., Hafeez, S., Omar, A. et al. (17 more authors) (2023) Randomised phase II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer: Late toxicity and cancer outcomes. In: Journal of Clinical Oncology. 2023 ASCO Genitourinary Cancers Symposium, 16-18 Feb 2023. American Society of Clinical Oncology .